GBA1 and Parkinson disease: Convergent genetic, transcriptomic, and metabolic evidence supports a dual-axis model of PD risk, comprising GBA1-sensitised lysosomal–lipid/redox pathways and GBA1-independent neuronal/endocrine routes.